Telix Pharmaceuticals Ltd (STU:T3X)

€ 14.31 -0.3 (-2.05%) Market Cap: 4.89 Bil Enterprise Value: 4.84 Bil PE Ratio: 162.08 PB Ratio: 19.98 GF Score: 75/100

Half Year 2024 Telix Pharmaceuticals Ltd Earnings Call Transcript
Aug 22, 2024

€12.19 (+1.50%)

Earnings
Telix Pharmaceuticals Ltd Investor Conference Call Transcript
Jul 31, 2024
Telix Pharmaceuticals Ltd Ordinary Shareholders Meeting Transcript
Apr 04, 2024
Full Year 2023 Telix Pharmaceuticals Ltd Earnings Call Transcript
Feb 22, 2024

Earnings
Telix Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Telix Pharmaceuticals Ltd Investor Webinar Transcript
Nov 20, 2023
Q3 2023 Telix Pharmaceuticals Ltd Activities Report Call Transcript
Oct 18, 2023
Half Year 2023 Telix Pharmaceuticals Ltd Earnings Call Transcript
Aug 23, 2023

Earnings
Q2 2023 Telix Pharmaceuticals Ltd Activities Report Call Transcript
Jul 19, 2023
Telix Pharmaceuticals Ltd Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer Transcript
Jun 21, 2023
Telix Pharmaceuticals Ltd at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Telix Pharmaceuticals Ltd Annual Shareholders Meeting Transcript
May 24, 2023
Telix Pharmaceuticals Ltd Grand Pharma Investor Webinar Transcript
Apr 20, 2023
Q1 2023 Telix Pharmaceuticals Ltd Activities Report Call Transcript
Apr 17, 2023
Full Year 2022 Telix Pharmaceuticals Ltd Earnings Call Transcript
Feb 27, 2023

Earnings
Telix Pharmaceuticals Ltd ASCO-GU ZIRCON Phase III Results Presentation Transcript
Feb 20, 2023
Q4 2022 Telix Pharmaceuticals Ltd Activities Report Call Transcript
Jan 17, 2023
Telix Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Telix Pharmaceuticals Ltd at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
Q3 2022 Telix Pharmaceuticals Ltd Activities Report Call Transcript
Oct 19, 2022
Half Year 2022 Telix Pharmaceuticals Ltd Earnings Call Transcript
Aug 17, 2022

Earnings

Telix Pharmaceuticals Ltd Investor Webinar Transcript

Nov 20, 2023 / 11:15PM GMT

Transcript

Operator

Thank you for standing by, and welcome to the Telix Pharmaceuticals Limited TLX591 ProstACT Expert Forum. (Operator Instructions) Today's format is a fireside chat hosted by Dr. Colin Hayward, Group Chief Medical Officer at Telix. Please go ahead.

Colin Hayward

Telix Pharmaceuticals Limited - Group Chief Medical Officer

Great. Thank you very much, and welcome to this interesting webinar PSMA Targeting Radiopharmaceuticals, the ProstACT therapy program with first-in-class our rADCs, TLX591 or Lu-rosopatamab tetraxetan. Now look, there's clearly growing interest in radiopharmaceuticals, in GU oncology as a whole, but especially in prostate cancer given recent data in PSMA 4, for example, the ongoing SPLASH study. But we, of course, have ongoing studies in a recent interim report of SELECT -- ProstACT SELECT, and you have seen the news about ProstACT GLOBAL recruiting the first patient in Australia. So that's a very exciting news for us here at Telix.

And this gives us an opportunity to revisit and reeducate the extensive development program to date and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.